Canine models for copper homeostasis disorders

International Journal of Molecular Sciences

Volumn 17, Issue 2, 2016, Pages

  Wu, Xiaoyan ^a   Leegwater, Peter A J ^a   Fieten, Hille ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

ATP7A; ATP7B; Bedlington terrier; COMMD1; Copper toxicosis; Genetics; Labrador retriever; Menkes disease; Nutrition; Wilson disease

Indexed keywords

COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE; MENKES PROTEIN; METALLOTHIONEIN; PENICILLAMINE; TRIENTINE; WILSON DISEASE PROTEIN; ZINC DERIVATIVE;

ANIMAL MODEL; AUTOIMMUNE DISEASE; CANINE MODEL; CHELATION THERAPY; COPPER HOMEOSTASIS; COPPER METABOLISM; GENE MAPPING; GENE MUTATION; HOMEOSTASIS; HUMAN; HYPERSENSITIVITY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MENKES SYNDROME; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANS GOLGI NETWORK; WILSON DISEASE; ANIMAL; CHROMOSOMAL MAPPING; DIET THERAPY; DISEASE MODEL; DOG; GENETIC ASSOCIATION STUDY; GENETICS; HEPATOLENTICULAR DEGENERATION; METABOLISM; METAL METABOLISM, INBORN ERRORS; ORGAN TRANSPLANTATION;

ANIMALS; CHELATION THERAPY; CHROMOSOME MAPPING; COPPER; DIET THERAPY; DISEASE MODELS, ANIMAL; DOGS; GENETIC ASSOCIATION STUDIES; HEPATOLENTICULAR DEGENERATION; HOMEOSTASIS; HUMANS; METAL METABOLISM, INBORN ERRORS; ORGAN TRANSPLANTATION;

EID: 84957559591     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17020196     Document Type: Review

References (115)

1. Osredkar, J.; Sustar, N. Copper and zinc, biological role and significance of Copper/Zinc imbalance. J. Clin. Toxicol. 2011. [CrossRef]
2. Opazo, C.M.; Greenough, M.A.; Bush, A.I. Copper: From neurotransmission to neuroproteostasis. Front. Aging Neurosci. 2014, 6, 143. [CrossRef] [PubMed]
3. Chan, W.Y.; Rennert, O.M. The role of copper in iron metabolism. Ann. Clin. Lab. Sci. 1980, 10, 338-344. [PubMed]
4. Horn, D.; Barrientos, A. Mitochondrial copper metabolism and delivery to cytochrome C oxidase. IUBMB Life 2008, 60, 421-429. [CrossRef] [PubMed]
5. Miranda, M.; Bartoli, G.; Ragnelli, A.M.; Cittadini, A.; Palozza, P.; Aimola, P.; Zarivi, O.; Bonfigli, A. Copper deficiency and pigmentation in the Rat: Morphofunctional aspects. J. Submicrosc. Cytol. Pathol. 1992, 24, 273-279. [PubMed]
6. Bousquet-Moore, D.; Prohaska, J.R.; Nillni, E.A.; Czyzyk, T.; Wetsel, W.C.; Mains, R.E.; Eipper, B.A. Interactions of peptide amidation and copper: Novel biomarkers and mechanisms of neural dysfunction. Neurobiol. Dis. 2010, 37, 130-140. [CrossRef] [PubMed]
7. O’Dell, B.L. Roles for iron and copper in connective tissue biosynthesis. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 1981, 294, 91-104. [CrossRef] [PubMed]
8. Kaler, S.G. ATP7A-related copper transport diseases-emerging concepts and future trends. Nat. Rev. Neurol. 2011, 7, 15-29. [CrossRef] [PubMed]
9. Menkes, J.H.; Alter, M.; Steigleder, G.K.; Weakley, D.R.; Sung, J.H. A Sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics 1962, 29, 764-779. [PubMed]
10. Vulpe, C.; Levinson, B.; Whitney, S.; Packman, S.; Gitschier, J. Isolation of a Candidate gene for menkes disease and evidence that it encodes a copper-transporting ATPase. Nat. Genet. 1993, 3, 7-13. [CrossRef] [PubMed]
11. Bull, P.C.; Thomas, G.R.; Rommens, J.M.; Forbes, J.R.; Cox, D.W. TheWilson disease gene is a putative copper transporting P-type ATPase similar to the menkes gene. Nat. Genet. 1993, 5, 327-337. [CrossRef] [PubMed]
12. Tanzi, R.E.; Petrukhin, K.; Chernov, I.; Pellequer, J.L.; Wasco, W.; Ross, B.; Romano, D.M.; Parano, E.; Pavone, L.; Brzustowicz, L.M. TheWilson disease gene is a copper transporting ATPase with homology to the menkes disease gene. Nat. Genet. 1993, 5, 344-350. [CrossRef]
13. Roberts, E.A.; Schilsky, M.L. American association for study of liver diseases (AASLD). Diagnosis and treatment ofWilson disease: An update. Hepatology 2008, 47, 2089-2111. [CrossRef] [PubMed]
14. Ferenci, P. Phenotype-genotype correlations in patients withWilson’s disease. Ann. N. Y. Acad. Sci. 2014, 1315, 1-5. [CrossRef] [PubMed]
15. Shimizu, N.; Yamaguchi, Y.; Aoki, T. Treatment and management ofWilson’s disease. Pediatr. Int. 1999, 41, 419-422. [CrossRef] [PubMed]
16. Sternlieb, I. Wilson’s disease: Indications for liver transplants. Hepatology 1984, 4, 15S-17S. [CrossRef] [PubMed]
17. Tanner, M.S. Role of Copper in Indian childhood cirrhosis. Am. J. Clin. Nutr. 1998, 67, 1074S-1081S. [PubMed]
18. Muller, T.; Feichtinger, H.; Berger, H.; Muller, W. Endemic tyrolean infantile cirrhosis: An ecogenetic disorder. Lancet 1996, 347, 877-880. [CrossRef]
19. Scheinberg, I.H.; Sternlieb, I. Wilson disease and idiopathic copper toxicosis. Am. J. Clin. Nutr. 1996, 63, 842S-845S. [PubMed]
20. Fieten, H.; Leegwater, P.A.; Watson, A.L.; Rothuizen, J. Canine models of copper toxicosis for understanding mammalian copper metabolism. Mamm. Genome 2012, 23, 62-75. [CrossRef] [PubMed]
21. van De Sluis, B.; Rothuizen, J.; Pearson, P.L.; van Oost, B.A.; Wijmenga, C. Identification of a new copper metabolism gene by positional cloning in a purebred dog population. Hum. Mol. Genet. 2002, 11, 165-173. [CrossRef] [PubMed]
22. Fieten, H.; Gill, Y.; Martin, A.J.; Concilli, M.; Dirksen, K.; van Steenbeek, F.G.; Spee, B.; van den Ingh, T.S.; Martens, E.C.; Festa, P. The Menkes and Wilson disease genes counteract in copper toxicosis in labrador retrievers: A new canine model for copper-metabolism disorders. Dis. Model. Mech. 2016, 9, 25-38. [CrossRef] [PubMed]
23. Shearin, A.L.; Ostrander, E.A. Leading the way: Canine models of genomics and disease. Dis. Model. Mech. 2010, 3, 27-34. [CrossRef]
24. Lindblad-Toh, K.; Wade, C.M.; Mikkelsen, T.S.; Karlsson, E.K.; Jaffe, D.B.; Kamal, M.; Clamp, M.; Chang, J.L.; Kulbokas, E.J.; Zody, M.C. Genome Sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005, 438, 803-819. [CrossRef] [PubMed]
25. Kasai, N.; Osanai, T.; Miyoshi, I.; Kamimura, E.; Yoshida, M.C.; Dempo, K. Clinico-pathological studies of LEC rats with hereditary hepatitis and hepatoma in the acute phase of hepatitis. Lab. Anim. Sci. 1990, 40, 502-505. [PubMed]
26. Theophilos, M.B.; Cox, D.W.; Mercer, J.F. The toxic milk mouse is a murine model of wilson disease. Hum. Mol. Genet. 1996, 5, 1619-1624. [CrossRef] [PubMed]
27. Huster, D.; Finegold, M.J.; Morgan, C.T.; Burkhead, J.L.; Nixon, R.; Vanderwerf, S.M.; Gilliam, C.T.; Lutsenko, S. Consequences of copper accumulation in the livers of the ATP7B/ (Wilson disease gene) knockout mice. Am. J. Pathol. 2006, 168, 423-434. [CrossRef] [PubMed]
28. Wang, Y.; Zhu, S.; Weisman, G.A.; Gitlin, J.D.; Petris, M.J. Conditional knockout of the Menkes disease copper transporter demonstrates its critical role in embryogenesis. PLoS ONE 2012, 7, e43039. [CrossRef] [PubMed]
29. Mason, K.E. A conspectus of research on copper metabolism and requirements of man. J. Nutr. 1979, 109, 1979-2066. [PubMed]
30. Moriya, M.; Ho, Y.H.; Grana, A.; Nguyen, L.; Alvarez, A.; Jamil, R.; Ackland, M.L.; Michalczyk, A.; Hamer, P.; Ramos, D. Copper is taken up efficiently from albumin and 2-macroglobulin by cultured human cells by more than one mechanism. Am. J. Physiol. Cell Physiol. 2008, 295, C708-C721. [CrossRef] [PubMed]
31. Van den Berghe, P.V.; Klomp, L.W. New Developments in the regulation of intestinal copper absorption. Nutr. Rev. 2009, 67, 658-672. [CrossRef] [PubMed]
32. Zhou, B.; Gitschier, J. hCTR1: A human gene for copper uptake identified by complementation in yeast. Proc. Natl. Acad. Sci. USA. 1997, 94, 7481-7486. [CrossRef] [PubMed]
33. Coyle, P.; Philcox, J.C.; Carey, L.C.; Rofe, A.M. Metallothionein: The multipurpose protein. Cell. Mol. Life Sci. 2002, 59, 627-647. [CrossRef] [PubMed]
34. Freedman, J.H.; Ciriolo, M.R.; Peisach, J. The role of glutathione in copper metabolism and toxicity. J. Biol. Chem. 1989, 264, 5598-5605. [PubMed]
35. Rosenzweig, A.C. Copper delivery by metallochaperone proteins. Acc. Chem. Res. 2001, 34, 119-128. [CrossRef] [PubMed]
36. Schmidt, P.J.; Kunst, C.; Culotta, V.C. Copper activation of superoxide dismutase 1 (SOD1) in vivo. Role for protein-protein interactions with the copper chaperone for SOD1. J. Biol. Chem. 2000, 275, 33771-33776. [CrossRef] [PubMed]
37. Amaravadi, R.; Glerum, D.M.; Tzagoloff, A. Isolation of a cDNA encoding the human homolog of COX17, a yeast gene essential for mitochondrial copper recruitment. Hum. Genet. 1997, 99, 329-333. [CrossRef] [PubMed]
38. Klomp, L.W.; Lin, S.J.; Yuan, D.S.; Klausner, R.D.; Culotta, V.C.; Gitlin, J.D. Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis. J. Biol. Chem. 1997, 272, 9221-9226. [PubMed]
39. Wang, Y.; Hodgkinson, V.; Zhu, S.; Weisman, G.A.; Petris, M.J. Advances in the Understanding of Mammalian Copper Transporters. Adv. Nutr. 2011, 2, 129-137. [CrossRef] [PubMed]
40. Kim, B.E.; Turski, M.L.; Nose, Y.; Casad, M.; Rockman, H.A.; Thiele, D.J. Cardiac copper deficiency activates a systemic signaling mechanism that communicates with the copper acquisition and storage organs. Cell Metab. 2010, 11, 353-363. [CrossRef] [PubMed]
41. Yanagimoto, C.; Harada, M.; Kumemura, H.; Abe, M.; Koga, H.; Sakata, M.; Kawaguchi, T.; Terada, K.; Hanada, S.; Taniguchi, E. Copper incorporation into ceruloplasmin is regulated by Niemann-Pick C1 protein. Hepatol. Res. 2011, 41, 484-491. [CrossRef] [PubMed]
42. Cater, M.A.; La Fontaine, S.; Shield, K.; Deal, Y.; Mercer, J.F. ATP7B mediates vesicular sequestration of copper: Insight into biliary copper excretion. Gastroenterology 2006, 130, 493-506. [CrossRef] [PubMed]
43. Nyasae, L.; Bustos, R.; Braiterman, L.; Eipper, B.; Hubbard, A. Dynamics of endogenous ATP7A (Menkes Protein) in intestinal epithelial cells: Copper-dependent redistribution between two intracellular sites. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292, G1181-G1194. [CrossRef] [PubMed]
44. Polishchuk, E.V.; Concilli, M.; Iacobacci, S.; Chesi, G.; Pastore, N.; Piccolo, P.; Paladino, S.; Baldantoni, D.; van IJzendoorn, S.C.; Chan, J. Wilson disease protein ATP7B utilizes lysosomal exocytosis to maintain copper homeostasis. Dev. Cell 2014, 29, 686-700. [CrossRef] [PubMed]
45. Phillips-Krawczak, C.A.; Singla, A.; Starokadomskyy, P.; Deng, Z.; Osborne, D.G.; Li, H.; Dick, C.J.; Gomez, T.S.; Koenecke, M.; Zhang, J.S. COMMD1 is linked to the WASH complex and regulates endosomal trafficking of the copper transporter ATP7A. Mol. Biol. Cell 2015, 26, 91-103. [CrossRef] [PubMed]
46. Vonk, W.I.; de Bie, P.; Wichers, C.G.; van den Berghe, P.V.; van der Plaats, R.; Berger, R.; Wijmenga, C.; Klomp, L.W.; van de Sluis, B. The copper-transporting capacity of ATP7A mutants associated with menkes disease is ameliorated by COMMD1 as a result of improved protein expression. Cell. Mol. Life Sci. 2012, 69, 149-163. [CrossRef] [PubMed]
47. De Bie, P.; van de Sluis, B.; Burstein, E.; van de Berghe, P.V.; Muller, P.; Berger, R.; Gitlin, J.D.; Wijmenga, C.; Klomp, L.W. Distinct Wilson’s disease mutations in ATP7B are associated with enhanced binding to COMMD1 and reduced stability of ATP7B. Gastroenterology 2007, 133, 1316-1326. [CrossRef] [PubMed]
48. Miyayama, T.; Hiraoka, D.; Kawaji, F.; Nakamura, E.; Suzuki, N.; Ogra, Y. Roles of COMM-domain-containing 1 in stability and recruitment of the copper-transporting ATPase in a mouse hepatoma cell line. Biochem. J. 2010, 429, 53-61. [CrossRef] [PubMed]
49. Goldstein, D.S.; Holmes, C.S.; Kaler, S.G. Relative efficiencies of plasma catechol levels and ratios for neonatal diagnosis of menkes disease. Neurochem. Res. 2009, 34, 1464-1468. [CrossRef]
50. Kaler, S.G.; Holmes, C.S.; Goldstein, D.S.; Tang, J.; Godwin, S.C.; Donsante, A.; Liew, C.J.; Sato, S.; Patronas, N. Neonatal diagnosis and treatment of menkes disease. N. Engl. J. Med. 2008, 358, 605-614. [CrossRef] [PubMed]
51. Abdel Ghaffar, T.Y.; Elsayed, S.M.; Elnaghy, S.; Shadeed, A.; Elsobky, E.S.; Schmidt, H. Phenotypic and genetic characterization of a cohort of pediatricWilson disease patients. BMC Pediatr. 2011, 11. [CrossRef] [PubMed]
52. Ferenci, P.; Czlonkowska, A.; Merle, U.; Ferenc, S.; Gromadzka, G.; Yurdaydin, C.; Vogel, W.; Bruha, R.; Schmidt, H.T.; Stremmel, W. Late-onsetWilson’s disease. Gastroenterology 2007, 132, 1294-1298. [CrossRef] [PubMed]
53. Das, S.K.; Ray, K. Wilson’s disease: An Update. Nat. Clin. Pract. Neurol. 2006, 2, 482-493. [CrossRef] [PubMed]
54. Ala, A.; Walker, A.P.; Ashkan, K.; Dooley, J.S.; Schilsky, M.L. Wilson’s disease. Lancet 2007, 369, 397-408. [CrossRef]
55. Wilson Disease Mutation Database. Available online: http://www.Wilsondisease.Med.Ualberta.Ca/Database.Asp (accessed on 7 October 2009).
56. Czlonkowska, A.; Gromadzka, G.; Chabik, G. Monozygotic female twins discordant for phenotype of Wilson’s disease. Mov. Disord. 2009, 24, 1066-1069. [CrossRef] [PubMed]
57. Gromadzka, G.; Rudnicka, M.; Chabik, G.; Przybylkowski, A.; Czlonkowska, A. Genetic variability in the methylenetetrahydrofolate reductase gene (MTHFR) affects clinical expression ofWilson’s disease. J. Hepatol. 2011, 55, 913-919. [CrossRef]
58. Schiefermeier, M.; Kollegger, H.; Madl, C.; Polli, C.; Oder, W.; Kuhn, H.; Berr, F.; Ferenci, P. The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson’s disease. Brain 2000, 123 Pt 3, 585-590. [CrossRef] [PubMed]
59. Merle, U.; Stremmel, W.; Gessner, R. Influence of homozygosity for methionine at codon 129 of the human prion gene on the onset of neurological and hepatic symptoms in Wilson disease. Arch. Neurol. 2006, 63, 982-985. [CrossRef]
60. Litwin, T.; Gromadzka, G.; Czlonkowska, A. Apolipoprotein E gene (APOE) genotype inWilson’s disease: impact on clinical presentation. Parkinsonism Relat. Disord. 2012, 18, 367-369. [CrossRef] [PubMed]
61. Gromadzka, G.; Czlonkowska, A. Influence of IL-1RN intron 2 variable number of tandem repeats (VNTR) polymorphism on the age at onset of neuropsychiatric symptoms in Wilson’s disease. Int. J. Neurosci. 2011, 121, 8-15. [CrossRef]
62. Weiss, K.H.; Runz, H.; Noe, B.; Gotthardt, D.N.; Merle, U.; Ferenci, P.; Stremmel, W.; Fullekrug, J. Genetic analysis of BIRC4/XIAP as a Putative modifier gene of wilson disease. J. Inherit. Metab. Dis. 2010, 33 (Suppl. 3), S233-S240. [CrossRef] [PubMed]
63. Schilsky, M.L. Treatment of Wilson’s disease: What are the relative roles of penicillamine, trientine, and zinc supplementation? Curr. Gastroenterol. Rep. 2001, 3, 54-59. [CrossRef] [PubMed]
64. Czlonkowska, A.; Litwin, T.; Karlinski, M.; Dziezyc, K.; Chabik, G.; Czerska, M. D-Penicillamine vs. zinc sulfate as first-line therapy for Wilson’s disease. Eur. J. Neurol. 2014, 21, 599-606. [CrossRef] [PubMed]
65. Boga, S.; Jain, D.; Schilsky, M.L. Trientine induced colitis during therapy forWilson disease: A case report and review of the literature. BMC Pharmacol. Toxicol. 2015, 16. 30-015-0031-z. [CrossRef] [PubMed]
66. Dahlman, T.; Hartvig, P.; Lofholm, M.; Nordlinder, H.; Loof, L.; Westermark, K. Long-term treatment of Wilson’s disease with Triethylene tetramine dihydrochloride (Trientine). QJM 1995, 88, 609-616. [PubMed]
67. Brewer, G.J.; Terry, C.A.; Aisen, A.M.; Hill, G.M. Worsening of neurologic syndrome in patients withWilson’s disease with initial Penicillamine therapy. Arch. Neurol. 1987, 44, 490-493. [CrossRef] [PubMed]
68. Brewer, G.J.; Turkay, A.; Yuzbaziyan-Gurkan, V. Development of neurologic symptoms in a patient with asymptomatic Wilson’s disease treated with penicillamine. Arch. Neurol. 1994, 51, 304-305. [CrossRef] [PubMed]
69. Ranucci, G.; di Dato, F.; Spagnuolo, M.I.; Vajro, P.; Iorio, R. Zinc Monotherapy is effective in Wilson’s disease patients with mild liver disease diagnosed in childhood: a retrospective study. Orphanet J. Rare Dis. 2014, 9. [CrossRef]
70. Marin, C.; Robles, R.; Parrilla, G.; Ramirez, P.; Bueno, F.S.; Parrilla, P. Liver Transplantation in Wilson’s disease: Are its indications established? Transplant. Proc. 2007, 39, 2300-2301. [CrossRef] [PubMed]
71. Tamura, S.; Sugawara, Y.; Kishi, Y.; Akamatsu, N.; Kaneko, J.; Makuuchi, M. Living-related liver transplantation for Wilson’s disease. Clin. Transplant. 2005, 19, 483-486. [CrossRef] [PubMed]
72. Emre, S.; Atillasoy, E.O.; Ozdemir, S.; Schilsky, M.; Rathna Varma, C.V.; Thung, S.N.; Sternlieb, I.; Guy, S.R.; Sheiner, P.A.; Schwartz, M.E. Orthotopic liver transplantation for Wilson’s disease: A single-center experience. Transplantation 2001, 72, 1232-1236. [CrossRef] [PubMed]
73. Bax, R.T.; Hassler, A.; Luck, W.; Hefter, H.; Krageloh-Mann, I.; Neuhaus, P.; Emmrich, P. Cerebral manifestation of Wilson’s disease successfully treated with liver transplantation. Neurology 1998, 51, 863-865. [CrossRef] [PubMed]
74. Podgaetz, E.; Chan, C. Liver transplant team. Liver transplantation for Wilson s disease: Our experience with review of the literature. Ann. Hepatol. 2003, 2, 131-134. [PubMed]
75. Nayak, N.C.; Chitale, A.R. Indian Childhood Cirrhosis (ICC) & ICC-like diseases: The changing scenario of facts vs. notions. Indian J. Med. Res. 2013, 137, 1029-1042. [PubMed]
76. Li, Y.; Togashi, Y.; Sato, S.; Emoto, T.; Kang, J.H.; Takeichi, N.; Kobayashi, H.; Kojima, Y.; Une, Y.; Uchino, J. Spontaneous hepatic copper accumulation in long-evans cinnamon rats with hereditary hepatitis. A model ofWilson’s disease. J. Clin. Investig. 1991, 87, 1858-1861. [CrossRef] [PubMed]
77. Haywood, S.; Muller, T.; Muller, W.; Heinz-Erian, P.; Tanner, M.S.; Ross, G. Copper-Associated Liver Disease in north ronaldsay sheep: A possible animal model for non-wilsonian hepatic copper toxicosis of infancy and childhood. J. Pathol. 2001, 195, 264-269. [CrossRef] [PubMed]
78. Puls, R. Mineral Levels in Animal Health: Diagnostic Data, 2nd ed.; Clearbrook, B.C., Ed.; Sherpa international, cop.: Dalhousie, QC, Canada, 1994.
79. Fieten, H.; Dirksen, K.; van den Ingh, T.S.; Winter, E.A.; Watson, A.L.; Leegwater, P.A.; Rothuizen, J. D-Penicillamine treatment of copper-associated hepatitis in labrador retrievers. Vet. J. 2013, 196, 522-527. [CrossRef] [PubMed]
80. Mandigers, P.J.; van den Ingh, T.S.; Bode, P.; Teske, E.; Rothuizen, J. Association between Liver Copper Concentration and subclinical hepatitis in doberman pinschers. J. Vet. Intern. Med. 2004, 18, 647-650. [CrossRef] [PubMed]
81. Twedt, D.C.; Hunsaker, H.A.; Allen, K.G. Use of 2,3,2-Tetramine as a hepatic copper chelating agent for treatment of copper hepatotoxicosis in bedlington terriers. J. Am. Vet. Med. Assoc. 1988, 192, 52-56. [PubMed]
82. Brewer, G.J.; Dick, R.D.; Schall, W.; Yuzbasiyan-Gurkan, V.; Mullaney, T.P.; Pace, C.; Lindgren, J.; Thomas, M.; Padgett, G. Use of zinc acetate to treat copper toxicosis in dogs. J. Am. Vet. Med. Assoc. 1992, 201, 564-568. [PubMed]
83. Twedt, D.C.; Sternlieb, I.; Gilbertson, S.R. Clinical, morphologic, and chemical studies on copper toxicosis of bedlington terriers. J. Am. Vet. Med. Assoc. 1979, 175, 269-275. [PubMed]
84. Hyun, C.; Filippich, L.J. Inherited canine copper toxicosis in australian bedlington terriers. J. Vet. Sci. 2004, 5, 19-28. [PubMed]
85. Vonk, W.I.; Bartuzi, P.; de Bie, P.; Kloosterhuis, N.; Wichers, C.G.; Berger, R.; Haywood, S.; Klomp, L.W.; Wijmenga, C.; van de Sluis, B. Liver-specific commd1 knockout mice are susceptible to hepatic copper accumulation. PLoS ONE 2011, 6, e29183. [CrossRef] [PubMed]
86. Klomp, A.E.; van de Sluis, B.; Klomp, L.W.; Wijmenga, C. The ubiquitously expressed MURR1 protein is absent in canine copper toxicosis. J. Hepatol. 2003, 39, 703-709. [CrossRef]
87. Su, L.C.; Ravanshad, S.; Owen, C.A.; McCall, J.T.; Zollman, P.E.; Hardy, R.M. A Comparison of copper-loading disease in bedlington terriers and Wilson’s disease in humans. Am. J. Physiol. 1982, 243, G226-G230. [PubMed]
88. Favier, R.P.; Spee, B.; Penning, L.C.; Rothuizen, J. Copper-induced hepatitis: The COMMD1 deficient dog as a translational animal model for human chronic hepatitis. Vet. Q. 2011, 31, 49-60. [CrossRef] [PubMed]
89. Hoffmann, G.; van den Ingh, T.S.; Bode, P.; Rothuizen, J. Copper-associated chronic hepatitis in labrador retrievers. J. Vet. Intern. Med. 2006, 20, 856-861. [CrossRef] [PubMed]
90. Shih, J.L.; Keating, J.H.; Freeman, L.M.; Webster, C.R. Chronic hepatitis in labrador retrievers: Clinical presentation and prognostic factors. J. Vet. Intern. Med. 2007, 21, 33-39. [CrossRef] [PubMed]
91. Smedley, R.; Mullaney, T.; Rumbeiha, W. Copper-Associated hepatitis in labrador retrievers. Vet. Pathol. 2009, 46, 484-490. [CrossRef] [PubMed]
92. Hoffmann, G.; Heuven, H.C.; Leegwater, P.A.; Jones, P.G.; van den Ingh, T.S.; Bode, P.; Rothuizen, J. Heritabilities of copper-accumulating traits in labrador retrievers. Anim. Genet. 2008, 39, 454. [CrossRef] [PubMed]
93. Haywood, S.; Rutgers, H.C.; Christian, M.K. Hepatitis and copper accumulation in skye terriers. Vet. Pathol. 1988, 25, 408-414. [CrossRef] [PubMed]
94. Thornburg, L.P.; Shaw, D.; Dolan, M.; Raisbeck, M.; Crawford, S.; Dennis, G.L.; Olwin, D.B. Hereditary copper toxicosis in West Highland white terriers. Vet. Pathol. 1986, 23, 148-154. [CrossRef] [PubMed]
95. Webb, C.B.; Twedt, D.C.; Meyer, D.J. Copper-associated liver disease in dalmatians: A review of 10 dogs (1998-2001). J. Vet. Intern. Med. 2002, 16, 665-668.
96. Karlsson, E.K.; Baranowska, I.; Wade, C.M.; Salmon Hillbertz, N.H.; Zody, M.C.; Anderson, N.; Biagi, T.M.; Patterson, N.; Pielberg, G.R.; Kulbokas, E.J., et al. Efficient mapping of mendelian traits in dogs through genome-wide association. Nat. Genet. 2007, 39, 1321-1328. [CrossRef] [PubMed]
97. Karlsson, E.K.; Lindblad-Toh, K. Leader of the pack: Gene mapping in dogs and other model organisms. Nat. Rev. Genet. 2008, 9, 713-725. [CrossRef] [PubMed]
98. Parker, H.G.; Kim, L.V.; Sutter, N.B.; Carlson, S.; Lorentzen, T.D.; Malek, T.B.; Johnson, G.S.; DeFrance, H.B.; Ostrander, E.A.; Kruglyak, L. Genetic structure of the purebred domestic dog. Science 2004, 304, 1160-1164. [CrossRef] [PubMed]
99. Mandigers, P.J.; van den Ingh, T.S.; Bode, P.; Rothuizen, J. Improvement in Liver Pathology After 4 Months of D-penicillamine in 5 doberman pinschers with subclinical hepatitis. J. Vet. Intern. Med. 2005, 19, 40-43. [CrossRef] [PubMed]
100. Kim, H.J.; Graham, D.W.; DiSpirito, A.A.; Alterman, M.A.; Galeva, N.; Larive, C.K.; Asunskis, D.; Sherwood, P.M. Methanobactin, a copper-acquisition compound from methane-oxidizing bacteria. Science 2004, 305, 1612-1615. [CrossRef] [PubMed]
101. Summer, K.H.; Lichtmannegger, J.; Bandow, N.; Choi, D.W.; DiSpirito, A.A.; Michalke, B. The biogenic methanobactin is an effective chelator for copper in a rat model for wilson disease. J. Trace Elem. Med. Biol. 2011, 25, 36-41. [CrossRef] [PubMed]
102. Fieten, H.; Hooijer-Nouwens, B.D.; Biourge, V.C.; Leegwater, P.A.; Watson, A.L.; van den Ingh, T.S.; Rothuizen, J. Association of Dietary Copper and Zinc Levels with Hepatic Copper and Zinc Concentration in Labrador Retrievers. J. Vet. Intern. Med. 2012, 26, 1274-1280. [CrossRef] [PubMed]
103. Fieten, H.; Biourge, V.C.; Watson, A.L.; Leegwater, P.A.; van den Ingh, T.S.; Rothuizen, J. Dietary management of labrador retrievers with subclinical hepatic copper accumulation. J. Vet. Intern. Med. 2015, 29, 822-827. [CrossRef] [PubMed]
104. Fieten, H.; Biourge, V.C.; Watson, A.L.; Leegwater, P.A.; van den Ingh, T.S.; Rothuizen, J. Nutritional management of inherited copper-associated hepatitis in the labrador retriever. Vet. J. 2014, 199, 429-433. [CrossRef] [PubMed]
105. Hoffmann, G.; Jones, P.G.; Biourge, V.; van den Ingh, T.S.; Mesu, S.J.; Bode, P.; Rothuizen, J. Dietary management of hepatic copper accumulation in labrador retrievers. J. Vet. Intern. Med. 2009, 23, 957-963. [CrossRef] [PubMed]
106. Yonezawa, K.; Nakagama, H.; Tajima, R.; Ushigome, M.; Ogra, Y.; Suzuki, K.T.; Yoshikawa, K.; Nagao, M. Effects of soy protein isolate on LEC rats, a model of Wilson disease: Mechanisms underlying enhancement of liver cell damage. Biochem. Biophys. Res. Commun. 2003, 302, 271-274. [CrossRef]
107. Yonezawa, K.; Nunomiya, S.; Daigo, M.; Ogra, Y.; Suzuki, K.T.; Enomoto, K.; Nakagama, H.; Yoshikawa, K.; Nagao, M. Soy protein isolate enhances hepatic copper accumulation and cell damage in LEC rats. J. Nutr. 2003, 133, 1250-1254. [PubMed]
108. Schilsky, M.L.; Scheinberg, I.H.; Sternlieb, I. Liver transplantation for Wilson’s disease: Indications and outcome. Hepatology 1994, 19, 583-587. [CrossRef] [PubMed]
109. Dalgetty, D.M.; Medine, C.N.; Iredale, J.P.; Hay, D.C. Progress and future challenges in stem cell-derived liver technologies. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297, G241-G248. [CrossRef] [PubMed]
110. Van Laecke, S.; Desideri, F.; Geerts, A.; van Vlierberghe, H.; Berrevoet, F.; Rogiers, X.; Troisi, R.; de Hemptinne, B.; Vanholder, R.; Colle, I. Hypomagnesemia and the risk of new-onset diabetes after liver transplantation. Liver Transpl. 2010, 16, 1278-1287. [CrossRef] [PubMed]
111. Huch, M.; Dorrell, C.; Boj, S.F.; van Es, J.H.; Li, V.S.; van de Wetering, M.; Sato, T.; Hamer, K.; Sasaki, N.; Finegold, M.J. In Vitro Expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature 2013, 494, 247-250. [CrossRef] [PubMed]
112. Huch, M.; Gehart, H.; van Boxtel, R.; Hamer, K.; Blokzijl, F.; Verstegen, M.M.; Ellis, E.; van Wenum, M.; Fuchs, S.A.; de Ligt, J. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 2015, 160, 299-312. [CrossRef] [PubMed]
113. Nantasanti, S.; Spee, B.; Kruitwagen, H.S.; Chen, C.; Geijsen, N.; Oosterhoff, L.A.; van Wolferen, M.E.; Pelaez, N.; Fieten, H.; Wubbolts, R.W. Disease modeling and gene therapy of copper storage disease in canine hepatic organoids. Stem Cell. Rep. 2015, 5, 895-907. [CrossRef]
114. Boch, J. TALEs of Genome Targeting. Nat. Biotechnol. 2011, 29, 135-136. [CrossRef] [PubMed]
115. Horvath, P.; Barrangou, R. CRISPR/Cas, the immune system of bacteria and archaea. Science 2010, 327, 167-170. [CrossRef] [PubMed]